High-mobility group box 1 promotes hepatocellular carcinoma progression through MIR-21-mediated matrix metalloproteinase activity

Cancer Research

Volumn 75, Issue 8, 2015, Pages 1645-1656

  Chen, Man ^a,b   Liu, Yao ^a,c   Varley, Patrick ^a   Chang, Ying ^b   He, Xing Xing ^b   Huang, Hai ^a   Tang, Daolin ^a   Lotze, Michael T ^a   Lin, Jusheng ^b   Tsung, Allan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c GANNAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MICRORNA 21; RECK PROTEIN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HMGB1 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; RECK PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL MIGRATION; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME REPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEPATITIS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; MURINE MODEL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; DISEASE COURSE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; DISEASE PROGRESSION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HEP G2 CELLS; HMGB1 PROTEIN; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; MICRORNAS; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84941920442     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2147     Document Type: Article

References (49)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-76.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100: 698-711.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140: 883-99.
4. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol 2011;2: 98.
5. Tang D, Kang R, Zeh HJ, LotzeMT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2011;1799: 131-40.
6. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, et al. Highmobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012;55: 1863-75.
7. Lotze MT, Tracey KJ.High-mobility group box 1 protein (HMGB1) : Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5: 331-42.
8. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007;204: 2913-23.
9. Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D. HMGB1 in cancer: Good, bad, or both? Clin Cancer Res 2013;19: 4046-57.
10. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418: 191-5.
11. Tian J, Avalos AM,MaoS-Y, Chen B, Senthil K,WuH, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8: 487-96.
12. O'Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF. MicroRNAs: Key modulators of posttranscriptional gene expression. Gastroenterology 2009;136: 17-25.
13. Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: Function, Detection, and Bioanalysis. Chem Rev 2013;113: 6207-33.
14. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. TrendsMol Med 2010;16: 257-67.
15. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4: 199-227.
16. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer 2010;10: 389-402.
17. Chan JA, Krichevsky AM, Kosik KS.MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65: 6029-33.
18. Iorio M V, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65: 7065-70.
19. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299: 425-36.
20. Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol 2010;53: 98-107.
21. Liu C, Gao F, Li B, Mitchel REJ, Liu X, Lin J, et al. TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21. Leukemia 2011;25: 1516-9.
22. Du Q, Park KS, Guo Z, He P, Nagashima M, Shao L, et al. Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res 2006;66: 7024-31.
23. Chang Y, Yan W, He X, Zhang L, Li C, Huang H, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012;143: 177-87.e8.
24. He X-X, Chang Y, Meng F-Y, Wang M-Y, Xie Q-H, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 2012;31: 3357-69.
25. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, LotzeMT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201: 1135-43.
26. He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res 2011;21: 159-68.
27. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120: 15-20.
28. FurumotoK,AriiS,MoriA,FuruyamaH,GorrinRivasMJ,NakaoT,etal.RECK gene expression in hepatocellular carcinoma: Correlation with invasionrelated clinicopathological factors and its clinical significance.Reverse-inducing-cysteine-rich protein with Kazal motifs. Hepatology 2001;33: 189-95.
29. Chen J-S, Wang Q, Fu X-H, Huang X-H, Chen X-L, Cao L-Q, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 2009;39: 177-86.
30. Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48: 2047-63.
31. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365: 1118-27.
32. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila M a. Inflammation and liver cancer: New molecular links. Ann N Y Acad Sci 2009;1155: 206-21.
33. Huang H, Evankovich J, Yan W, Nace G, Zhang L, Ross M, et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology 2011;54: 999-1008.
34. Tili E, Michaille J-J, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 2013;253: 167-84.
35. Polytarchou C, Iliopoulos D, HatziapostolouM, Kottakis F, Maroulakou I, Struhl K, et al. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 2011;71: 4720-31.
36. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013;52: 297-303.
37. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. Micro-RNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133: 647-58.
38. Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, et al. HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene 2013;32: 3296-305.
39. Limana F, Esposito G, D'Arcangelo D, Di Carlo A, Romani S, Melillo G, et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS ONE 2011;6: E19845.
40. Mardente S, Mari E, Consorti F, Di Gioia C, Negri R, Etna M, et al. HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep 2012;28: 2285-9.
41. Park JS, Svetkauskaite D, He Q, Kim J-Y, Strassheim D, Ishizaka A, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279: 7370-7.
42. Park JS, Arcaroli J, YumH-K, Yang H, Wang H, Yang K-Y, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003;284: C870-9.
43. Liu Y, Fuchs J, Li C, Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-Induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle 2010;9: 3423-7.
44. Lepiller Q, Abbas W, Kumar A, Tripathy MK, Herbein G. HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS ONE 2013;8: E59591.
45. Li L, Li H. Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors. Cancer Biol Ther 2013;14: 796-805.
46. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008;28: 5369-80.
47. Yan X-L, Jia Y-L, Chen L, Zeng Q, Zhou J-N, Fu C-J, et al. Hepatocellular carcinoma-Associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 2013;57: 2274-86.
48. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 2008;88: 1358-66.
49. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 2010;29: 29.